Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow. Giving the patient their healthy stem cells will help their bone marrow make new stem cells that become red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well busulfan, melphalan, and thiotepa work in treating patients who are undergoing an autologous stem cell transplant for Hodgkin's or non-Hodgkin's lymphoma.
Key facts
- Study ID
- NCT00238433
- Run by
- OHSU Knight Cancer Institute
- People needed
- 37
- Starts
- 2005-03-01
- Expected to finish
- 2016-12-01
- Last updated by the study team
- 2017-09-27
Who can join
Age: any, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Knight Cancer Institute at Oregon Health and Science University — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.